
The US-based pharmaceutical company Eli Lilly's price reduction on its already cheapest insulin products signifies the tough competition on the US insulin market, in which the company is fighting for its market share with, for instance, Denmark's Novo Nordisk.
So says Senior Chief Analyst at Sydbank Søren Løntoft Hansen to Marketwire.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app